Drug Policy:

Carvykti™ (ciltacabtagene autoleucel)

POLICY NUMBER UM ONC_1460	**SUBJECT** Carvykti™ (ciltacabtagene autoleucel)	**DEPT/PROGRAM** UM Dept	**PAGE 1 OF 3**
DATES COMMITTEE REVIEWED 04/13/22, 05/11/22, 02/08/23, 02/14/24, 05/08/24	**APPROVAL DATE** May 08, 2024	**EFFECTIVE DATE** May 31, 2024	**COMMITTEE APPROVAL DATES** 04/13/22, 05/11/22, 02/08/23, 02/14/24, 05/08/24
PRIMARY BUSINESS OWNER: UM		**COMMITTEE/BOARD APPROVAL** Utilization Management Committee	
NCQA STANDARDS UM 2		**ADDITIONAL AREAS OF IMPACT**	
CMS REQUIREMENTS	**STATE/FEDERAL REQUIREMENTS**	**APPLICABLE LINES OF BUSINESS** Commercial, Exchange, Medicaid, Medicare	

I. PURPOSE

To define and describe the accepted indications for Carvykti (ciltacabtagene autoleucel) usage in the treatment of cancer, including FDA approved indications, and off-label indications.

Evolent is responsible for processing all medication requests from network ordering providers. Medications not authorized by Evolent may be deemed as not approvable and therefore not reimbursable.

The use of this drug must be supported by one of the following: FDA approved product labeling, CMS-approved compendia, National Comprehensive Cancer Network (NCCN), American Society of Clinical Oncology (ASCO) clinical guidelines, or peer-reviewed literature that meets the requirements of the CMS Medicare Benefit Policy Manual Chapter 15.

II. INDICATIONS FOR USE/INCLUSION CRITERIA

A. Continuation requests for a not-approvable medication shall be exempt from this Evolent policy provided:

1. The member has not experienced disease progression on the requested medication AND
2. The requested medication was used within the last year without a lapse of more than 30 days of having an active authorization AND
3. Additional medication(s) are not being added to the continuation request.

B. Multiple Myeloma

1. Carvykti (ciltacabtagene autoleucel) may be used for adult members with relapsed/refractory multiple myeloma who have received at least 1 prior line of therapy, including a proteasome inhibitor (e.g., bortezomib, carfilzomib, ixazomib) and an immunomodulatory agent (e.g., lenalidomide, thalidomide, pomalidomide), and are refractory to lenalidomide.

III. EXCLUSION CRITERIA

A. Disease progression on or after Carvykti (ciltacabtagene autoleucel) or prior treatment with chimeric antigen receptor T (CAR-T) therapy towards CD19 antigen (e.g., Abecma (idecabtagene vicleucel)].

B. Concurrent use with other anti-myeloma therapy.

C. Member does NOT have measurable disease defined as any of the folllowing:

1. Serum monoclonal paraprotein (M-protein) level more than or equal to 1.0 g/dL or urine M-protein level greater than or equal to 200 mg/24hr OR
2. Light chain multiple myeloma without measurable disease in the serum or the urine: Serum immunoglobulin free light chain 10 mg/dL and abnormal serum immunoglobulin kappa lambda free light chain ratio.

D. Does not exceed duration limit as one time administration.

E. Dosing exceeds single dose limit of Carvykti (ciltacabtagene autoleucel) 1×10^8 CAR-positive viable T cells per single-dose infusion.

F. Investigational use of Carvykti (ciltacabtagene autoleucel) with an off-label indication that is not sufficient in evidence or is not generally accepted by the medical community. Sufficient evidence that is not supported by CMS recognized compendia or acceptable peer reviewed literature is defined as any of the following:

1. Whether the clinical characteristics of the patient and the cancer are adequately represented in the published evidence.
2. Whether the administered chemotherapy/biologic therapy/immune therapy/targeted therapy/other oncologic therapy regimen is adequately represented in the published evidence.
3. Whether the reported study outcomes represent clinically meaningful outcomes experienced by patients. Generally, the definitions of Clinically Meaningful outcomes are those recommended by ASCO, e.g., Hazard Ratio of less than 0.80 and the recommended survival benefit for OS and PFS should be at least 3 months.
4. Whether the experimental design, considering the drugs and conditions under investigation, is appropriate to address the investigative question. (For example, in some clinical studies, it may be unnecessary or not feasible to use randomization, double blind trials, placebos, or crossover).
5. That non-randomized clinical trials with a significant number of subjects may be a basis for supportive clinical evidence for determining accepted uses of drugs.
6. That case reports are generally considered uncontrolled and anecdotal information and do not provide adequate supportive clinical evidence for determining accepted uses of drugs.
7. That abstracts (including meeting abstracts) without the full article from the approved peer-reviewed journals lack supporting clinical evidence for determining accepted uses of drugs.

IV. MEDICATION MANAGEMENT

A. Please refer to the FDA label/package insert for details regarding these topics.

V. APPROVAL AUTHORITY

A. Review – Utilization Management Department

B. Final Approval – Utilization Management Committee

VI. ATTACHMENTS

A. None

VII. REFERENCES

A. San-Miguel J, et al. Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma. The New England Journal of Medicine. 2023 July 27; 389(4): 335-347. DOI: 10.1056/NEJMoa2303379

B. Berdeja JG, et al. CARTITUDE-1 Clinical Trial. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet. 2021 Jul 24;398(10297):314-324.

C. Carvykti prescribing information. Janssen Biotech, Inc. Horsham, PA 2024.

D. Ellis LM, et al. American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes. J Clin Oncol. 2014 Apr 20;32(12):1277-80.

E. Medicare Benefit Policy Manual Chapter 15 Covered Medical and Other Health Services: https://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/Downloads/bp102c15.pdf.

F. Current and Resolved Drug Shortages and Discontinuations Reported to the FDA: http://www.accessdata.fda.gov/scripts/drugshortages/default.cfm.